02 Nov 22

Cambridge, UK, November 2nd, 2022: o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine transglycosylase (TGT) enzyme pathway against a range of autoimmune diseases without interfering with the body’s immune system. 

As part of the kickstarter programme, o2h discovery will be providing small molecule synthetic chemistry to deliver improved medicines for patients with autoimmune disease, including Multiple Sclerosis.

Jason Rutt, CEO said:

“We are very excited and appreciative of the o2h discovery kickstarter programme. Having had some prior experience of both the medicinal, synthetic chemistry and biology screening capabilities we have decided to run our programme fully integrated under o2h discovery. I believe this is the kickstart we need to move our programme and thus company forward.”

Sunil Shah, CEO of o2h Ventures said:

“We are really happy to welcome Azadyne onto our kickstarter programme. They are working on a very exciting (and hot!) area of RNA Biology and we felt the o2h kickstarter programme could make a real difference to get to the next value inflection points for the company.”

About o2h discovery:

Founded in 2005, o2h discovery is a Contract Research Organisation which has an integrated drug discovery platform operating from its state-of-the-art research centre in India and The Mill SciTech Park, Cambridge, UK. We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development. 

For more information about o2h discovery, visit: https://www.o2h.com or email marketing@o2h.com

About Azadyne:

Azadyne is a biotech spin-out company from Trinity College Dublin founded by Professors Stephen Connon, Vincent Kelly, Mike Southern and CEO, Dr. Jason Rutt. Azadyne’s aim is to exploit innovative technology to disrupt the therapeutic options for autoimmune disease. Azadyne focuses on an unexplored pathway within the body and offers a novel approach to the treatment of autoimmune disease – a therapeutic area suffering from considerable unmet medical need.

For more information visit: https://www.azadyne.com/